Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jul, 2014 | Pages:
59 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Vulvovaginal Candidiasis - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Vulvovaginal Candidiasis - Pipeline Review, H2 2014', provides an overview of the Vulvovaginal Candidiasis's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Vulvovaginal Candidiasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Vulvovaginal Candidiasis and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Vulvovaginal Candidiasis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Vulvovaginal Candidiasis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Vulvovaginal Candidiasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Vulvovaginal Candidiasis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Vulvovaginal Candidiasis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Vulvovaginal Candidiasis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Vulvovaginal Candidiasis Overview 7 Therapeutics Development 8 Pipeline Products for Vulvovaginal Candidiasis - Overview 8 Pipeline Products for Vulvovaginal Candidiasis - Comparative Analysis 9 Vulvovaginal Candidiasis - Therapeutics under Development by Companies 10 Vulvovaginal Candidiasis - Therapeutics under Investigation by Universities/Institutes 11 Vulvovaginal Candidiasis - Pipeline Products Glance 12 Clinical Stage Products 12 Unknown Stage Products 13 Vulvovaginal Candidiasis - Products under Development by Companies 14 Vulvovaginal Candidiasis - Products under Investigation by Universities/Institutes 15 Vulvovaginal Candidiasis - Companies Involved in Therapeutics Development 16 Actavis plc 16 Pevion Biotech AG 17 NovaDigm Therapeutics, Inc. 18 Grupo Ferrer Internacional, S.A. 19 Viamet Pharmaceuticals, Inc. 20 Mirati Therapeutics Inc. 21 Vulvovaginal Candidiasis - Therapeutics Assessment 22 Assessment by Monotherapy Products 22 Assessment by Target 23 Assessment by Mechanism of Action 25 Assessment by Route of Administration 27 Assessment by Molecule Type 29 Drug Profiles 31 MGCD-290 - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 albaconazole - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 arasertaconazole - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 NDV-3 - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 VT-1161 - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 NDV-3A - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 PEV-7 - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 Candiplus - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 Glycerol Monolaurate - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 Vulvovaginal Candidiasis - Recent Pipeline Updates 43 Vulvovaginal Candidiasis - Dormant Projects 48 Vulvovaginal Candidiasis - Discontinued Products 49 Vulvovaginal Candidiasis - Product Development Milestones 50 Featured News & Press Releases 50 Jul 10, 2014: Viamet Reports Additional Positive Interim Results of Phase 2 Study of VT-1161 in Patients with Moderate to Severe Acute Vulvovaginal Candidiasis 50 Feb 18, 2014: Viamet Reports Positive Interim Results of Phase 2 Study of VT-1161 50 Sep 26, 2013: NovaDigm Therapeutics Initiates Phase 1b/2a Clinical Trial with NDV-3 Vaccine in Recurrent Vulvovaginal Candidiasis 51 Sep 24, 2013: Viamet Pharmaceuticals Expands Phase 2 Clinical Program with Novel Antifungal Agent VT-1161 52 Sep 05, 2013: Viamet Pharmaceuticals Initiates Phase 2 Clinical Program with Novel Antifungal Agent VT-1161 53 Mar 18, 2013: MethylGene Reports Results Of Phase II Trial Of MGCD290 53 Dec 19, 2012: MethylGene Completes Enrollment In Phase II Trial Of MGCD290 54 Oct 22, 2012: Methylgene Presents Phase I Data Of Anti-fungal Drug Candidate MGCD290 At IDWeek 2012 55 Oct 10, 2012: MethylGene Provides Clinical Update On MGCD290 New Antifungal Therapeutic Program 55 Sep 11, 2012: MethylGene Presents Preclinical Data Of Antifungal Candidate MGCD290 At ICAAC 2012 56 Appendix 58 Methodology 58 Coverage 58 Secondary Research 58 Primary Research 58 Expert Panel Validation 58 Contact Us 59 Disclaimer 59
List of Tables Number of Products under Development for Vulvovaginal Candidiasis, H2 2014 8 Number of Products under Development for Vulvovaginal Candidiasis - Comparative Analysis, H2 2014 9 Number of Products under Development by Companies, H2 2014 10 Number of Products under Investigation by Universities/Institutes, H2 2014 11 Comparative Analysis by Clinical Stage Development, H2 2014 12 Comparative Analysis by Unknown Stage Development, H2 2014 13 Products under Development by Companies, H2 2014 14 Products under Investigation by Universities/Institutes, H2 2014 15 Vulvovaginal Candidiasis - Pipeline by Actavis plc, H2 2014 16 Vulvovaginal Candidiasis - Pipeline by Pevion Biotech AG, H2 2014 17 Vulvovaginal Candidiasis - Pipeline by NovaDigm Therapeutics, Inc., H2 2014 18 Vulvovaginal Candidiasis - Pipeline by Grupo Ferrer Internacional, S.A., H2 2014 19 Vulvovaginal Candidiasis - Pipeline by Viamet Pharmaceuticals, Inc., H2 2014 20 Vulvovaginal Candidiasis - Pipeline by Mirati Therapeutics Inc., H2 2014 21 Assessment by Monotherapy Products, H2 2014 22 Number of Products by Stage and Target, H2 2014 24 Number of Products by Stage and Mechanism of Action, H2 2014 26 Number of Products by Stage and Route of Administration, H2 2014 28 Number of Products by Stage and Molecule Type, H2 2014 30 Vulvovaginal Candidiasis Therapeutics - Recent Pipeline Updates, H2 2014 43 Vulvovaginal Candidiasis - Dormant Projects, H2 2014 48 Vulvovaginal Candidiasis - Discontinued Products, H2 2014 49
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
